Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Medicaid reimbursements, pharmacy benefit margins or risk-adjustment accruals across dozens of filings can overwhelm even seasoned analysts. Centene’s disclosures span hundreds of pages, and locating a single note on state contract renewals often feels like finding a needle in a haystack. That’s why investors searching for “Centene SEC filings explained simply� or wondering “where to read a Centene quarterly earnings report 10-Q filing� start here.
Stock Titan’s AI-powered analysis converts complex language into clear takeaways. Uploads from EDGAR trigger real-time alerts, so “Centene Form 4 insider transactions real-time� appear within minutes. Our platform highlights what matters in each document: the medical loss ratio buried in a “Centene annual report 10-K simplified�, contract wins detailed in a “Centene 8-K material events explained�, or share purchases flagged under “Centene insider trading Form 4 transactions�. Need a quick view of executive equity moves? The dashboard aggregates “Centene executive stock transactions Form 4� alongside context, saving hours of manual work.
Beyond form names, we connect filings to Centene’s business drivers. AI summaries break down Medicaid redetermination impacts quarter by quarter for “Centene earnings report filing analysis�, spotlight shifts in premium revenue across states, and surface board proposals inside the “Centene proxy statement executive compensation� section. Whether you’re a portfolio manager comparing MCO peers or a policy analyst “understanding Centene SEC documents with AI�, you’ll find every 10-K, 10-Q, 8-K and Form 4—with plain-English insights—updated the moment Centene hits send.
Centene Corporation disclosed that Director Thomas R. Greco notified the company on August 12, 2025 that he will resign effective August 22, 2025 due to increased professional responsibilities after his appointment as chief executive officer of FleetPride, Inc., a privately-held automotive parts company. The filing states his resignation was not the result of any dispute or disagreement with Centene or its Board. The Board has reduced its size to nine directors effective upon his resignation.
Harris Associates L.P. and Harris Associates, Inc. file Amendment No. 1 to a Schedule 13G reporting ownership in Centene Corp. The filing shows Harris beneficially owns 20,418,731 shares of Centene common stock, representing 4.1% of the class. Harris reports sole voting power for 18,043,616 shares and sole dispositive power for 20,418,731 shares. The filing states these shares are held in the ordinary course of business and not for the purpose of changing control. The document identifies the filing parties, addresses, CUSIP 15135B101, and includes certifications and signatures dated 08/14/2025.
Centene director Kenneth A. Burdick filed an amended Initial Statement of Beneficial Ownership to correct previously reported holdings. The Form 3/A reports 360,802 shares of Centene (CNC) and states the original Form 3 filed on 01/14/2022 and subsequent Form 4s overstated his direct holdings by 29,533 shares. The event date listed is 01/05/2022 and the amendment was executed by an attorney-in-fact on 08/11/2025.
Centene Corporation director and chief executive officer Sarah London reported an open-market purchase of common stock on 08/08/2025. The filing shows acquisition of 19,230 shares at a weighted average price of $25.49�$25.50, increasing her reported direct beneficial ownership to 845,275 shares. The ownership total explicitly includes 591,998 shares represented by previously-granted restricted stock units and performance stock units reported at target levels and subject to vesting.
The report also discloses 13,449 performance-style stock options with an exercise price of $81.85, tied to a grant with a performance condition that the common stock close at or above $100 for 20 consecutive trading days before they may become exercisable. The form was executed by an attorney-in-fact.